Involvement of PML proteins in treatment of acute promyelocytic leukemia with arsenic trioxide / 浙江大学学报·医学版
Journal of Zhejiang University. Medical sciences
;
(6): 541-551, 2018.
Article
Dans Chinois
| WPRIM
| ID: wpr-775281
ABSTRACT
Promyelocytic leukemia (PML) protein, a tumor suppressor, plays an important role in patients with acute promyelocytic leukemia (APL) receiving arsenic trioxide (AsO) therapy. APL is a M3 subtype of acute myeloid leukemia (AML), which is characterized by expression of PML-RARα (P/R) fusion protein, leading to the oncogenesis. AsO is currently used as the first-line drug for patients with APL, and the mechanism may beAsO directly binds to PML part of P/R protein and induces multimerization of related proteins, which further recruits different functional proteins to reform PML nuclear bodies (PML-NBs), and finally it degraded by SUMOylation and ubiquitination proteasomal pathway. Gene mutations may lead to relapse and drug resistance after AsO treatment. In this review, we discuss the structure and function of PML proteins; the pathogenesis of APL induced by P/R fusion protein; the involvement of PML protein in treatment of APL patient with AsO; and explain how PML protein mutations could cause resistance to AsO therapy.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Leucémie aiguë promyélocytaire
/
Protéines de fusion oncogènes
/
Chimie
/
Résistance aux médicaments antinéoplasiques
/
Utilisations thérapeutiques
/
Traitement médicamenteux
/
Protéine de la leucémie promyélocytaire
/
Trioxyde d'arsenic
/
Génétique
/
Métabolisme
Limites du sujet:
Humains
langue:
Chinois
Texte intégral:
Journal of Zhejiang University. Medical sciences
Année:
2018
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS